Cpmc-R.K. Davies Medical Center
- Type
- Teaching hospital
- Where
- Santa Rosa, CA
- Medicare CCN
- 050008
- Received
- $861,057 in 117 records, 2022 ($5,047 general, $856,010 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 2 | $5,047 |
| 2022 | Research payment | 115 | $856,010 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Edwards Lifesciences Corporation | 23 | $228,209 | 2022 |
| E.R. Squibb & Sons, L.L.C. | 9 | $163,860 | 2022 |
| Boston Scientific Corporation | 26 | $138,062 | 2022 |
| Novartis Pharmaceuticals Corporation | 4 | $117,291 | 2022 |
| Abbott Laboratories | 32 | $70,913 | 2022 |
| Incyte Corporation | 5 | $41,300 | 2022 |
| Biogen, Inc. | 5 | $40,936 | 2022 |
| MorphoSys AG | 1 | $23,056 | 2022 |
| GENZYME CORPORATION | 3 | $16,700 | 2022 |
| ARGENX US, INC. | 3 | $12,400 | 2022 |
| PENTAX of America, Inc. | 1 | $2,547 | 2022 |
| Alnylam Pharmaceuticals Inc. | 1 | $2,500 | 2022 |
| Eli Lilly and Company | 2 | $1,786 | 2022 |
| AtriCure, Inc. | 1 | $973 | 2022 |
| Clovis Oncology, Inc. | 1 | $520 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 115 | $856,010 |
| Long term medical supply or device loan | 1 | $2,547 |
| Space rental or facility fees (teaching hospital only) | 1 | $2,500 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Boston Scientific Corporation | $3,312 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-12-28 | Incyte Corporation | $1,500 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-12-19 | GENZYME CORPORATION | $3,500 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443 | 2022 | |
| 2022-12-19 | GENZYME CORPORATION | $500 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443 | 2022 | |
| 2022-12-15 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2022 |
| 2022-12-14 | E.R. Squibb & Sons, L.L.C. | $22,040 | Research payment | Cash or cash equivalent | PhIII Stage 3/4 Resectable Mel Adj Rela+Nivo vs Nivo - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunothera | 2022 | |
| 2022-12-12 | Edwards Lifesciences Corporation | $65,686 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2022 | |
| 2022-12-08 | Edwards Lifesciences Corporation | $2,475 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2022 | |
| 2022-12-08 | Edwards Lifesciences Corporation | $1,500 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2022 | |
| 2022-12-06 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | OPTION | 2022 |
| 2022-12-05 | PENTAX of America, Inc. | $2,547 | Long term medical supply or device loan | Cash or cash equivalent | ULTRASOUND GASTROSCOPE Device, Gastroenterology | 2022 | |
| 2022-11-30 | Boston Scientific Corporation | $2,208 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-11-30 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-11-21 | E.R. Squibb & Sons, L.L.C. | $3,376 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Stage II B/C Opdivo Mono | 2022 |
| 2022-11-21 | Boston Scientific Corporation | $2,000 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | OPTION | 2022 |
| 2022-11-14 | Edwards Lifesciences Corporation | $796 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2022 | |
| 2022-11-09 | Abbott Laboratories | $1,634 | Research payment | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure | Antiplatelet Removal and HemocompatIbility Events in the HeartMate 3 Pump | 2022 |
| 2022-11-03 | Incyte Corporation | $18,750 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2022 | |
| 2022-11-02 | GENZYME CORPORATION | $12,700 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443 | 2022 | |
| 2022-10-31 | Boston Scientific Corporation | $2,000 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-10-20 | Incyte Corporation | $1,550 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2022 | |
| 2022-10-17 | Boston Scientific Corporation | $1,709 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | OPTION | 2022 |
| 2022-10-03 | E.R. Squibb & Sons, L.L.C. | $20,000 | Research payment | Cash or cash equivalent | Phenoptypic and transcriptional characterization of patient and PDX-derived tumors | 2022 | |
| 2022-09-30 | Boston Scientific Corporation | $4,371 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-09-30 | Boston Scientific Corporation | $2,484 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-09-23 | Edwards Lifesciences Corporation | $13,500 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2022 | |
| 2022-09-21 | ARGENX US, INC. | $7,200 | Research payment | Cash or cash equivalent | Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar | 2022 | |
| 2022-09-21 | ARGENX US, INC. | $3,500 | Research payment | Cash or cash equivalent | Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar | 2022 | |
| 2022-09-21 | ARGENX US, INC. | $1,700 | Research payment | Cash or cash equivalent | Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar | 2022 | |
| 2022-09-20 | Boston Scientific Corporation | $854 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | OPTION | 2022 |
| 2022-09-16 | Edwards Lifesciences Corporation | $2,160 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2022 | |
| 2022-09-15 | Incyte Corporation | $750 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-09-08 | MorphoSys AG | $23,056 | Research payment | Cash or cash equivalent | MONJUVI Drug, Oncology | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2022 |
| 2022-08-31 | Boston Scientific Corporation | $13,894 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-08-30 | Incyte Corporation | $18,750 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-08-17 | Abbott Laboratories | $8,810 | Research payment | Cash or cash equivalent | Device, Structural Heart | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2022 |
| 2022-08-17 | Abbott Laboratories | $4,475 | Research payment | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure | Antiplatelet Removal and HemocompatIbility Events in the HeartMate 3 Pump | 2022 |
| 2022-08-16 | Boston Scientific Corporation | $270 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | OPTION | 2022 |
| 2022-08-12 | AtriCure, Inc. | $973 | Research payment | Cash or cash equivalent | ATRICLIP LAA EXCLUSION SYSTEM Device, CARDIOVASCULAR | PIVOTAL STUDY OF A DUAL EPICARDIAL & ENDOCARDIAL PROCEDURE (DEEP) APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT OR | 2022 |
| 2022-08-08 | Biogen, Inc. | $23,572 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismuta | 2022 | |
| 2022-08-04 | Edwards Lifesciences Corporation | $13,500 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2022 | |
| 2022-07-31 | Boston Scientific Corporation | $7,890 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-07-18 | Boston Scientific Corporation | $2,822 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | OPTION | 2022 |
| 2022-07-14 | Edwards Lifesciences Corporation | $14,990 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2022 | |
| 2022-07-08 | E.R. Squibb & Sons, L.L.C. | $21,289 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Ph III Nivo ipi vs Nivo in Stage IIIb c or IV Adj Melanoma - A Phase 3 Randomized Study of Adjuvant Immunotherapy with N | 2022 |
| 2022-07-07 | Edwards Lifesciences Corporation | $48,241 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2022 | |
| 2022-07-07 | Abbott Laboratories | $12,016 | Research payment | Cash or cash equivalent | Device, Structural Heart | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2022 |
| 2022-07-07 | Edwards Lifesciences Corporation | $2,389 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2022 | |
| 2022-06-30 | E.R. Squibb & Sons, L.L.C. | $28,555 | Research payment | Cash or cash equivalent | PhIII Early Melanoma Stage 3 4 Resectable in All Comers | 2022 | |
| 2022-06-30 | Boston Scientific Corporation | $7,392 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-06-30 | Abbott Laboratories | $44 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | A Randomized Controlled Trial Comparing the FreeStyle Libre 2 Continuous Glucose Monitoring vs Point of Care Glucose Tes | 2022 |
| 2022-06-30 | Abbott Laboratories | $43 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | A Randomized Controlled Trial Comparing the FreeStyle Libre 2 Continuous Glucose Monitoring vs Point of Care Glucose Tes | 2022 |
| 2022-06-30 | Abbott Laboratories | $23 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | A Randomized Controlled Trial Comparing the FreeStyle Libre 2 Continuous Glucose Monitoring vs Point of Care Glucose Tes | 2022 |
| 2022-06-30 | Abbott Laboratories | $8 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | A Randomized Controlled Trial Comparing the FreeStyle Libre 2 Continuous Glucose Monitoring vs Point of Care Glucose Tes | 2022 |
| 2022-06-30 | Abbott Laboratories | $8 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | A Randomized Controlled Trial Comparing the FreeStyle Libre 2 Continuous Glucose Monitoring vs Point of Care Glucose Tes | 2022 |
| 2022-06-30 | Abbott Laboratories | $3 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | A Randomized Controlled Trial Comparing the FreeStyle Libre 2 Continuous Glucose Monitoring vs Point of Care Glucose Tes | 2022 |
| 2022-06-30 | Abbott Laboratories | $1 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | A Randomized Controlled Trial Comparing the FreeStyle Libre 2 Continuous Glucose Monitoring vs Point of Care Glucose Tes | 2022 |
| 2022-06-30 | Abbott Laboratories | $1 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | A Randomized Controlled Trial Comparing the FreeStyle Libre 2 Continuous Glucose Monitoring vs Point of Care Glucose Tes | 2022 |
| 2022-06-21 | Boston Scientific Corporation | $3,167 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | OPTION | 2022 |
| 2022-06-03 | Alnylam Pharmaceuticals Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | 2022 | |
| 2022-05-31 | Boston Scientific Corporation | $21,371 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-05-23 | Edwards Lifesciences Corporation | $26,844 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2022 | |
| 2022-05-16 | Boston Scientific Corporation | $1,255 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | OPTION | 2022 |
| 2022-05-12 | Edwards Lifesciences Corporation | $10,363 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2022 | |
| 2022-05-11 | Abbott Laboratories | $30 | Research payment | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure | Antiplatelet Removal and HemocompatIbility Events in the HeartMate 3 Pump | 2022 |
| 2022-05-04 | Biogen, Inc. | $1,974 | Research payment | Cash or cash equivalent | Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amy | 2022 | |
| 2022-05-03 | Biogen, Inc. | $426 | Research payment | Cash or cash equivalent | PLEGRIDY Biological, Neurology | Plegridy (peginterferon 1a) Real World Effectiveness and Safety Observational Program | 2022 |
| 2022-04-30 | Boston Scientific Corporation | $17,027 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-04-20 | Abbott Laboratories | $12,067 | Research payment | Cash or cash equivalent | Device, Structural Heart | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2022 |
| 2022-04-18 | Boston Scientific Corporation | $1,661 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | OPTION | 2022 |
| 2022-04-07 | Clovis Oncology, Inc. | $520 | Research payment | Cash or cash equivalent | RUBRACA Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2022 |
| 2022-03-31 | Boston Scientific Corporation | $6,768 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-03-21 | Boston Scientific Corporation | $1,150 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | OPTION | 2022 |
| 2022-03-17 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | Device, Structural Heart | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2022 |
| 2022-03-17 | Abbott Laboratories | $700 | Research payment | Cash or cash equivalent | Device, Structural Heart | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2022 |
| 2022-03-14 | Edwards Lifesciences Corporation | $13,060 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2022 | |
| 2022-03-11 | Eli Lilly and Company | $6 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 | |
| 2022-03-10 | Edwards Lifesciences Corporation | $1,000 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2022 | |
| 2022-03-10 | Edwards Lifesciences Corporation | $1,000 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2022 | |
| 2022-03-10 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure | Antiplatelet Removal and HemocompatIbility Events in the HeartMate 3 Pump | 2022 |
| 2022-03-10 | Abbott Laboratories | $150 | Research payment | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure | Antiplatelet Removal and HemocompatIbility Events in the HeartMate 3 Pump | 2022 |
| 2022-03-01 | Novartis Pharmaceuticals Corporation | $3,484 | Research payment | Cash or cash equivalent | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III STUDY COMPARING THE COMBINATION OF PDR001 DABRAFENIB AND TRAMETIN | 2022 | |
| 2022-02-28 | Boston Scientific Corporation | $21,990 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-02-24 | Abbott Laboratories | $1,350 | Research payment | Cash or cash equivalent | AGILIS HISPRO Device, Electrophysiology | Physiologic Pacing Registry | 2022 |
| 2022-02-24 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | AGILIS HISPRO Device, Electrophysiology | Physiologic Pacing Registry | 2022 |
| 2022-02-23 | Novartis Pharmaceuticals Corporation | $18,174 | Research payment | Cash or cash equivalent | MAYZENT Drug, NEUROSCIENCE | A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP PLACEBO CONTROLLED VARIABLE TREATMENT DURATION STUDY EVALUATING THE | 2022 |
| 2022-02-22 | Boston Scientific Corporation | $1,150 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | OPTION | 2022 |
| 2022-02-17 | Edwards Lifesciences Corporation | $1,550 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2022 | |
| 2022-02-17 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Device, Vascular | Safety and Effectiveness of TactiFlex Ablation Catheter, Sensor Enabled (TactiFlex SE) for the Treatment of Drug Refract | 2022 |
| 2022-02-17 | Abbott Laboratories | $900 | Research payment | Cash or cash equivalent | ENSITE PRECISION Device, Electrophysiology | LSI (Lesion Index) Workflow Post-Market Observational Study | 2022 |
| 2022-02-17 | Abbott Laboratories | $550 | Research payment | Cash or cash equivalent | Device, Vascular | Safety and Effectiveness of TactiFlex Ablation Catheter, Sensor Enabled (TactiFlex SE) for the Treatment of Drug Refract | 2022 |
| 2022-02-17 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | ENSITE PRECISION Device, Electrophysiology | LSI (Lesion Index) Workflow Post-Market Observational Study | 2022 |
| 2022-02-17 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Device, Structural Heart | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2022 |
| 2022-02-17 | Abbott Laboratories | $150 | Research payment | Cash or cash equivalent | Device, Structural Heart | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2022 |
| 2022-02-16 | Abbott Laboratories | $1,425 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2022 |
| 2022-02-11 | E.R. Squibb & Sons, L.L.C. | $4,590 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Study Adj GEJ & Esoph US EU mono - A Randomized, Multicenter, Double-Blind, Phase III Study of Adjuvant Nivolu | 2022 |
| 2022-02-10 | Abbott Laboratories | $135 | Research payment | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure | Antiplatelet Removal and HemocompatIbility Events in the HeartMate 3 Pump | 2022 |
| 2022-02-09 | Abbott Laboratories | $17,237 | Research payment | Cash or cash equivalent | Device, Structural Heart | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2022 |
| 2022-02-03 | Edwards Lifesciences Corporation | $4,146 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2022 | |
| 2022-02-03 | Edwards Lifesciences Corporation | $1,274 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2022 | |
| 2022-02-03 | Edwards Lifesciences Corporation | $650 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2022 | |
| 2022-02-03 | Novartis Pharmaceuticals Corporation | $250 | Research payment | Cash or cash equivalent | TAFINLAR Drug, ONCOLOGY | COMBIAD A PHASE III RANDOMIZED DOUBLE BLIND STUDY OF DABRAFENIB GSK2118436 IN COMBINATION WITH TRAMETINIB GSK1120212 VER | 2022 |
| 2022-02-02 | Novartis Pharmaceuticals Corporation | $95,383 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | PROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF) | 2022 |
| 2022-02-02 | Abbott Laboratories | $878 | Research payment | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure | Antiplatelet Removal and HemocompatIbility Events in the HeartMate 3 Pump | 2022 |
| 2022-01-31 | Boston Scientific Corporation | $8,646 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-01-24 | Eli Lilly and Company | $1,780 | Research payment | Cash or cash equivalent | CYRAMZA Drug, Oncology | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF RAMUCIRUMAB AND BEST SUPPORTIVE CARE -BSC- VERSUS PLACEBO | 2022 |
| 2022-01-21 | E.R. Squibb & Sons, L.L.C. | $44,442 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Stage II B C Opdivo Mono | 2022 |
| 2022-01-20 | E.R. Squibb & Sons, L.L.C. | $19,170 | Research payment | Cash or cash equivalent | EMPLICITI Biological, Oncology | A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previo | 2022 |
| 2022-01-18 | Biogen, Inc. | $9,337 | Research payment | Cash or cash equivalent | A Phase 1 Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmac | 2022 | |
| 2022-01-18 | Boston Scientific Corporation | $1,161 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | OPTION | 2022 |
| 2022-01-13 | Edwards Lifesciences Corporation | $2,175 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2022 | |
| 2022-01-13 | Edwards Lifesciences Corporation | $500 | Research payment | Cash or cash equivalent | CLASP IIF (2018-07) | 2022 | |
| 2022-01-13 | Edwards Lifesciences Corporation | $337 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2022 | |
| 2022-01-10 | E.R. Squibb & Sons, L.L.C. | $398 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant HCC mono vs placebo | 2022 |
| 2022-01-10 | Edwards Lifesciences Corporation | $67 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2022 | |
| 2022-01-06 | Abbott Laboratories | $2,268 | Research payment | Cash or cash equivalent | Device, Structural Heart | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2022 |
| 2022-01-04 | Biogen, Inc. | $5,627 | Research payment | Cash or cash equivalent | An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect of Disease Progression of | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Santa Rosa, CA, county Sonoma County, CA, state California; placed by its city name.
| Measure | Place (city or town) Santa Rosa, CA | County Sonoma County, CA | State California |
|---|---|---|---|
| Population B01003 | 177,090 | 485,040 | 39,287,377 |
| Population, 2020 census P1 | 178,127 | 488,863 | 39,538,223 |
| Median age B01002 | 41.2 | 42.9 | 37.9 |
| Under 18 B01001 | 20.1% | 19.0% | 22.0% |
| 65 and over B01001 | 19.0% | 21.5% | 15.7% |
| Households B11001 | 68,321 | 190,998 | 13,548,091 |
| Foreign born B05002 | 21.2% | 16.8% | 27.0% |
| Median household income B19013 | $99,060 | $104,674 | $99,122 |
| Median family income B19113 | $120,944 | $126,900 | $113,346 |
| Per capita income B19301 | $52,066 | $56,640 | $49,513 |
| Poverty rate B17001 | 9.7% | 8.9% | 12.0% |
| Unemployment rate B23025 | 6.3% | 5.7% | 6.6% |
| Civilian labor force B23025 | 96,710 | 258,155 | 20,068,466 |
| Mean commute (minutes) B08013 | 22.9 | 25.1 | 28.7 |
| Bachelor's degree or higher B15003 | 35.1% | 38.5% | 37.1% |
| Housing units B25001 | 71,382 | 207,699 | 14,644,735 |
| Owner-occupied B25003 | 56.7% | 62.6% | 55.9% |
| Renters B25003 | 43.3% | 37.4% | 44.1% |
| Median home value B25077 | $713,900 | $815,500 | $734,700 |
| Median gross rent B25064 | $2,152 | $2,158 | $2,036 |
| White, not Hispanic B03002 | 48.7% | 57.9% | 33.8% |
| Black B03002 | 1.9% | 1.5% | 5.2% |
| Hispanic or Latino B03002 | 37.4% | 30.0% | 40.2% |
| Asian B03002 | 6.3% | 4.3% | 15.3% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Santa Rosa, CA.
Comments